News

Zymenex has received FDA approval of its Investigational New Drug (IND) application for its enzyme Metazym, which is intended for use in the treatment of the rare, lysosomal disease Metachromatic Leukodystrophy (MLD). The company is now preparing for Phase 2 clinical trials in the USA.

COPENHAGEN – The investments are key links in Sunstone Capital’s strategy to help strengthen growth potential for established biotech firms in the Oresund Region. Sunstone has done this by contributing its own money as well as by raising capital from local and international investors.

Egalet

Danish biotech company Egalet strengthens management by appointing internationally experienced CFO

Danish specialty pharmaceutical company Egalet has appointed Mr Bertrand Damour as its Chief Financial Officer and Executive Vice President.

Mr Damour has extensive experience in the international financial markets and biotechnology industry and will reinforce Egalet’s position in the global pharmaceutical and biotechnology sector.

Zymenenex

Novel Natural History Study to answer question in Rare Disease

The Natural History Study of the rare lysosomal disease alpha-Mannosidosis will answer the question; why the rare disease develops as it does? The first patients have been included in the first Natural History Study of the disease, being conducted under the HUE-MAN project, a 6th framework, EU grant supported initiative.